Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on November 14, 2018. The registrant is a Nevada corporation and an emerging growth company. The report details a corporate governance action regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate amendment and does not contain financial performance data.
Material Changes
On November 14, 2018, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State. The material change is an increase in the number of authorized shares of common stock from 236,000,000 to 500,000,000. This amendment does not affect the number of issued and outstanding shares but increases the capacity for future share issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the standard implications of increasing authorized share capital. The amendment was approved by the majority stockholder and the board of directors on October 5, 2018.
Investor Verification Checklist
- Verify the exact number of currently issued and outstanding shares to assess the dilution potential of the new 500,000,000 authorized share limit.
- Review the Definitive Information Statement on Schedule 14C filed on October 25, 2018, for details on the approval process.
- Confirm the company's current cash position and burn rate to understand the necessity of increasing authorized shares for potential future fundraising.
- Check for any subsequent filings regarding the actual issuance of shares from the newly authorized pool.